Both Merck & Co. Inc.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb Co.’s Opdivo (nivolumab) were approved by the FDA to treat advanced metastatic melanoma last year, but that’s only the start of the possibilities for the PD-1 pathway drugs. (See BioWorld Today, Sept. 5, 2014.) Read More
SAN FRANCISCO – The Washington-based Alliance for Regenerative Medicine (ARM) presented its state-of-the-industry briefing at the Biotech Showcase meeting last week, which re-affirmed the regenerative medicine and advanced therapies industry is extremely vibrant. Read More
SAN FRANCISCO - With all the leading biotechnology and big pharma companies presenting to packed audiences at the J.P. Morgan Healthcare Conference that concluded last Thursday, was all this concentrated intelligence enough to move biotech’s market valuation during the course of the event? Read More
